Medical University Pierre et Marie Curie, UFR Paris VI, 91-105 Boulevard de l'Hôpital, Paris, France.
Eur J Cancer. 2013 Aug;49(12):2643-53. doi: 10.1016/j.ejca.2013.04.017. Epub 2013 May 28.
Prognosis of patients with pancreatic adenocarcinoma (PAC) remains poor. S100A2 has been recently suggested as a negative prognostic biomarker in PAC. We aimed to investigate its prognostic and/or predictive value in a large independent multicentric cohort of patients with resected PAC.
Sequential samples of 471 patients were retrospectively collected; 142 patients did not receive adjuvant treatment (30%) and 329 (70%) received an adjuvant treatment. We measured protein levels of S100A2 by semiquantitative immunohistochemistry with tissue microarrays and correlated with patients' overall survival (OS) and disease-free survival (DFS).
S100A2 protein status was obtained in 462 (98%) patients. Its expression was low, moderate or high in 59%, 12% and 2% of cases, respectively. It was not correlated with DFS or OS in the whole population, neither in the subgroup of patients who did not receive adjuvant treatment. However among patients who received an adjuvant therapy, moderate/high levels of S100A2 were significantly associated with longer OS and DFS in multivariate analysis (hazard ratios of 0.63, p=0.022 and 0.67, p=0.017, respectively), whereas low S100A2 was not. Interaction tests for adjuvant therapy were statistically significant both for the OS and the DFS (p=0.001 and p=0.023, respectively). On multivariate analysis, S100A2 retained independent predictive values (OS: p<0.001, DFS: p=0.003) with a significant benefit of adjuvant therapy for those patients with moderate/high S100A2.
S100A2 expression predicts longer DFS and OS in patients treated with adjuvant therapy and should be evaluated as a predictive biomarker.
胰腺导管腺癌（PAC）患者的预后仍然较差。最近有人提出 S100A2 是 PAC 的一个负预后生物标志物。我们旨在通过对接受根治性手术的 PAC 患者的大型独立多中心队列进行研究，来调查 S100A2 的预后和/或预测价值。
回顾性收集了 471 例患者的连续样本；其中 142 例患者未接受辅助治疗（30%），329 例（70%）接受了辅助治疗。我们通过组织微阵列的半定量免疫组化测量 S100A2 的蛋白水平，并将其与患者的总生存（OS）和无病生存（DFS）相关联。
在 462 例（98%）患者中获得了 S100A2 蛋白状态。其表达分别在 59%、12%和 2%的病例中为低、中或高。在整个人群中，S100A2 的表达与 DFS 或 OS 均无相关性，在未接受辅助治疗的患者亚组中也无相关性。然而，在接受辅助治疗的患者中，S100A2 的中/高水平在多变量分析中与更长的 OS 和 DFS 显著相关（OS 的风险比为 0.63，p=0.022 和 DFS 的风险比为 0.67，p=0.017），而低 S100A2 则没有。对于 OS 和 DFS，辅助治疗的交互检验均具有统计学意义（p=0.001 和 p=0.023）。在多变量分析中，S100A2 保留了独立的预测价值（OS：p<0.001，DFS：p=0.003），对于 S100A2 中/高水平的患者，辅助治疗具有显著的获益。
S100A2 的表达预测了接受辅助治疗的患者的DFS 和 OS 更长，应该作为一种预测生物标志物进行评估。
